查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1735638

帶狀皰疹疫苗市場，2026-2032：依產品類型、疫苗類型、通路、年齡層和地區分類

Zoster Vaccine Market By Product Type (Zostavax, Shingrix), Vaccine Type (Live Attenuated Vaccine, Recombinant Vaccine), Distribution Channel (Hospital Pharmacy, Retail Pharmacy), Age Group (Above 50 to 65 Age, Above 65 Age), & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

帶狀皰疹疫苗市場評估-2026-2032

慢性病盛行率的上升和人口老化正在推動帶狀皰疹疫苗的需求。此外，人們越來越意識到接種疫苗有助於預防由水痘帶狀皰疹病毒引起的帶狀皰疹，預計將推動帶狀皰疹疫苗市場的發展。預計2024年帶狀皰疹疫苗的銷售額將超過16.2億美元，到2032年將達到34.7億美元。

此外，疫苗技術的發展和新型更有效疫苗的開發也有望推動帶狀皰疹疫苗市場的成長。已開發國家醫療政策的持續實施，使該市場在 2026 年至 2032 年期間的複合年成長率達到約 10%。

帶狀皰疹疫苗市場定義/概述

帶狀皰疹疫苗，通常稱為帶狀皰疹疫苗，是預防帶狀皰疹的重要措施。帶狀皰疹是由水痘帶狀皰疹病毒重新運作引起的，這種病毒也會導致水痘。該疫苗含有減毒病毒，可刺激免疫系統產生抗體，進而預防或減輕帶狀皰疹的嚴重程度。該疫苗的主要用途是預防50歲以上人口的帶狀皰疹，這些人隨著老齡化，免疫力會逐漸減弱，因此患病風險會增加。此外，該疫苗還有助於減少與帶狀皰疹相關的併發症，例如慢性疼痛和神經系統問題。

目前，帶狀皰疹疫苗主要有兩種：Shingrix 和 Zostavax，進一步的研究正在探索更有效、更廣泛應用的疫苗選擇。目前正在努力提高全球，特別是中低收入國家的帶狀皰疹疫苗可及性，以減輕全球帶狀皰疹相關疾病的負擔。

全球帶狀皰疹患者的增加是否會推動帶狀皰疹疫苗市場的成長？

由於人口老化、免疫力減弱以及癌症和愛滋病毒等慢性疾病盛行率增加等因素，全球帶狀皰疹的盛行率正在上升，這將推動帶狀皰疹疫苗市場的成長。

因此，隨著越來越多人意識到接種疫苗的預防帶狀皰疹的重要性，未來幾年帶狀皰疹疫苗的需求可能會增加。這為帶狀皰疹疫苗市場的成長帶來了巨大的機會。例如，葛蘭素史克於2023年4月25日推出了一款帶狀皰疹疫苗（Zoster）。據葛蘭素史克稱，該疫苗的有效率為90%，可提供至少10年的帶狀皰疹保護期。

人們越來越意識到接種疫苗對預防帶狀皰疹的重要性，這推動了帶狀皰疹疫苗市場的需求。全球人口老化也促進了市場的成長，因為老年人更容易感染帶狀皰疹。例如，一項針對印度人口的血清流行率研究表明，到40歲時，超過90%的參與者體內持有病毒，這使得他們更容易感染帶狀皰疹。為了預防帶狀皰疹和帶狀皰疹後遺症神經痛， 定序疫苗已核准用於50歲及以上成年人。

此外，疫苗技術的進步以及新型、更有效疫苗的研發預計將推動市場成長。所有這些因素預計將推動帶狀皰疹疫苗市場在未來幾年穩步成長。

帶狀皰疹疫苗的高成本是否會阻礙帶狀皰疹疫苗市場的成長？

帶狀皰疹疫苗的高成本是許多人（尤其是在低收入國家）接種疫苗的一大障礙，並可能阻礙帶狀皰疹疫苗市場的成長。造成此成本障礙的因素很多，包括研發的複雜性、生產流程、配送物流，以及需要多次接種才能確保有效免疫。

此外，醫療保健提供者和醫療機構在購買帶狀皰疹疫苗等高成本疫苗時可能面臨財務限制，尤其是在報銷率較低的環境中，這可能會進一步限制獲得疫苗接種的機會，減少整體需求並限制市場成長。

人們日益意識到嚴格的監管規定，這無疑會對帶狀皰疹疫苗市場的成長構成挑戰。疫苗核准流程冗長且成本高昂，這可能會延遲新疫苗的上市，並限制其供應。此外，嚴格的安全性和有效性監管要求可能會使新的製造商難以進入市場。

此外，疫苗引發皮疹的增多也可能阻礙帶狀皰疹疫苗市場的成長。接種疫苗後出現皮疹等不良反應可能會降低人們對疫苗的信心，從而減少需求，最終影響市場的成長。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第2章調查方法

  • 資料探勘
  • 二次調查
  • 初步調查
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 觀點

第3章執行摘要

  • 全球帶狀皰疹疫苗市場概況
  • 2024-2030年全球帶狀皰疹疫苗市場規模預測
  • 帶狀皰疹疫苗全球市場價值估計與預測（2024-2030）
  • 帶狀皰疹疫苗全球生態圖譜（2022年分享）
  • 競爭分析：漏斗圖
  • 帶狀皰疹疫苗全球市場絕對商機
  • 全球帶狀皰疹疫苗市場吸引力分析（按地區）
  • 全球帶狀皰疹疫苗市場吸引力分析（按產品類型）
  • 全球帶狀皰疹疫苗市場吸引力分析（按疫苗類型）
  • 依年齡層對全球帶狀皰疹疫苗市場的吸引力分析
  • 全球帶狀皰疹疫苗市場吸引力分析（按銷售管道）
  • 全球帶狀皰疹疫苗市場（依產品類型）
  • 全球帶狀皰疹疫苗市場（依疫苗類型）
  • 全球帶狀皰疹疫苗市場（按年齡層）
  • 全球帶狀皰疹疫苗市場依銷售管道
  • 未來市場機會

第4章 市場展望

  • 全球帶狀皰疹疫苗市場的變化
  • 帶狀皰疹疫苗的全球市場前景
  • 市場促進因素
    • 帶狀皰疹盛行率不斷上升
    • 提高對帶狀皰疹的認知
  • 市場限制
    • 疫苗高成本
  • 市場趨勢
    • 人口老化
  • 市場機會
    • 疫苗技術開發
  • 波特五力分析
    • 新進入者的威脅
    • 替代品的威脅
    • 供應商的議價能力
    • 買家的議價能力
    • 競爭對手之間的競爭強度
  • 宏觀經濟分析
  • 價值鏈分析
  • 定價分析
  • 規定
    • 沙烏地阿拉伯食品藥物管理局（SFDA）
  • 產品生命線

第5章 依產品類型分類的市場

  • 概述
  • 全球帶狀皰疹疫苗市場：依產品類型分析基點佔有率（bps）
  • 佐斯塔瓦克斯
  • 定序
  • 天空之星

第6章 疫苗類型市場

  • 概述
  • 全球帶狀皰疹疫苗市場：按疫苗類型分類的基點佔有率（bps）分析
  • 減毒活病毒疫苗
  • 重組疫苗

第7章 分銷通路市場

  • 概述
  • 全球帶狀皰疹疫苗市場：按分銷管道分類的基點佔有率（bps）分析
  • 私人的
  • 民眾

第8章 年齡層市場

  • 概述
  • 全球帶狀皰疹疫苗市場：依年齡層分析Basis Point Share（bps）
  • 50至65歲
  • 65歲或以上
  • 18歲以上，50歲以下

第9章 區域市場

  • 概述
    • 印度
    • 台灣
    • 泰國
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 土耳其
    • 巴西
    • 墨西哥
    • 阿根廷

第10章 競爭格局

  • 概述
  • 競爭場景
  • 市場排名分析
  • 區域足跡
  • 公司在各行業的足跡
  • 王牌矩陣
    • 積極的
    • 前線
    • 新興
    • 創新者

第11章 公司簡介

  • GLAXOSMITHKLINE PLC.
  • MERCK & CO., INC.
  • SK BIOSCIENCES（SK CHEMICALS）
  • GENEONE LIFE SCIENCE
  • PFIZER
  • CANSINO BIOLOGICS INC.
  • VACCITECH
  • INOVIO PHARMACEUTICALS, INC.
  • CUREVO INC.
Product Code: 35907

Zoster Vaccine Market Valuation - 2026-2032

The rising prevalence of chronic diseases and the aging population are driving the demand for zoster vaccine market. Additionally, the zoster vaccine can be attributed to the increasing awareness regarding the importance of vaccination in helping to prevent shingles caused by the varicella-zoster virus is anticipated to fuel the market to surpass revenue of USD 1.62 Billion valued in 2024 and reach USD 3.47 Billion by 2032.

Also, growing advancements in vaccine technology and the development of new and more effective vaccines are also expected to propel the growth of the zoster vaccine market. The increasing implementation of healthcare policies in developed nations is enabling the market grow at a CAGR of about 10% from 2026 to 2032.

Zoster Vaccine Market: Definition/ Overview

The zoster vaccine, commonly referred to as the shingles vaccine, is a crucial preventive measure against herpes zoster, an ailment triggered by the reactivation of the varicella-zoster virus, which also causes chickenpox. This vaccine contains a weakened form of the virus, stimulating the immune system to produce antibodies that can prevent or mitigate the severity of shingles. Its primary application lies in preventing shingles in individuals aged 50 and older, who are at an increased risk due to age-related decline in immunity. Additionally, the vaccine helps in reducing complications associated with shingles, such as chronic pain and neurological issues.

Currently, there are two main types of zoster vaccines available that are Shingrix and Zostavax and future research is exploring even more effective options with broader applications. The Protection and require fewer doses, potential expansion of recommendations to include younger age groups or those with specific medical conditions, exploration of combination vaccines for simplified immunization schedules, and efforts to enhance global access, particularly in low- and middle-income countries, to alleviate the burden of shingles-related illness on a global scale.

Will Increasing Cases of Herpes Zoster Worldwide Drive the Growth of the Zoster Vaccine Market?

The prevalence of herpes zoster disease is rising globally due to factors such as the aging population, weakened immune systems, and increased prevalence of chronic diseases such as cancer and HIV will drive the growth of the zoster vaccine market

As a result, the demand for zoster vaccine is likely to increase in the coming years as more people become aware of the importance of vaccination to prevent shingles. This presents a significant opportunity for the growth of the zoster vaccine market. For instance, on 25 April 2023, GSK launched the shingles vaccine, (herpes zoster). GSK said the vaccine had 90% efficacy and provided at least 10 years of protection against herpes zoster.

The growing awareness among people about the importance of vaccination to prevent shingles is driving the demand for the zoster vaccine market. The aging population worldwide is also contributing to the growth of the market as older adults are more susceptible to shingles. For instance, according seroprevalence study in Indian subjects showed that by the age of 40 years, more than 90% of the participants had this virus in their bodies and were therefore vulnerable to shingles. For the prevention of shingles and post-herpetic neuralgia, Shingrix vaccine has been approved for adults above 50 years.

Furthermore, advancements in vaccine technology and the development of new and more effective vaccines are expected to boost the growth of the market. All these factors suggest that the zoster vaccine market is poised for steady growth in the coming years.

Will The High Cost of Zoster Vaccine Hamper the Growth of the Zoster Vaccine Market?

Increasing the high cost of the zoster vaccine can be a significant barrier for many people, especially in low-income countries, and it could potentially hamper the growth of the zoster vaccine market. This cost barrier stems from various factors, including the complexities of research and development, manufacturing processes, distribution logistics, and the necessity for multiple doses to ensure effective immunity.

Additionally, healthcare providers and institutions may face financial constraints in purchasing high-cost vaccines like the zoster vaccine, particularly in settings where reimbursement rates are inadequate. This can further limit access to vaccination and reduce overall demand, constraining market growth.

Growing awareness of stringent regulations can indeed pose a challenge to the growth of the zoster vaccine market. The regulatory approval process for vaccines can be lengthy and costly, which can delay the launch of new vaccines and limit their availability. Additionally, regulatory requirements for safety and efficacy can be strict, which can make it difficult for new manufacturers to enter the market.

Furthermore, the increasing occurrence of vaccine rashes can indeed hinder the growth of the zoster vaccine market. When people experience rashes or other adverse reactions after receiving a vaccine, it can lead to a decrease in confidence in the vaccine and reduce demand for it. This can ultimately impact the growth of the market.

Category-Wise Acumens

Will the Rising Utilization of the Shingrix Vaccine Drive the Zoster Vaccine Market?

The rising use of the Shingrix vaccine is expected to drive the zoster vaccine market. Shingrix is a highly effective vaccine for preventing zoster, and it has been shown to provide longer-lasting protection than other available vaccines. This vaccine provides a high level of immunity for at least 7 years after vaccination, as more people become aware of the benefits of Shingrix the demand for the vaccine is expected to increase, which will help to drive growth in the zoster vaccine market.

Additionally, during the forecast period, there will be a rise in demand for these vaccinations due to increasing awareness of the disease's effects and the growing number of countries that have approved Shingrix for use as a vaccine. For instance, GSK announced the shingles vaccine Shingrix in India. This vaccine is recommended for people aged 50 years and above to protect against shingles.

Increasing awareness of the importance of shingles vaccination will drive the zoster vaccine market Companies may invest in marketing efforts to differentiate their products and highlight their efficacy and safety profiles. Additionally, the drive for innovation may lead to the development of new vaccine formulations or delivery methods to better meet the needs of consumers.

The surge in demand for shingles vaccines propels market expansion, prompting vaccine manufacturers to bolster production capacities to satisfy healthcare providers and consumer requirements. This heightened production not only addresses immediate demand but also fosters increased investment in research and development. As revenue streams grow, manufacturers allocate more resources to R&D endeavors, aiming to enhance vaccine efficacy, safety, and accessibility

Increasing demand for technological developments in vaccine formulation, delivery, and production are improving the accessibility, safety, and efficacy of vaccinations. This accelerates the market's growth for zoster vaccines, providing better preventive treatments and enhanced public health results.

Will Increasing Demand for Recombinant Vaccine will Boost the Zoster Vaccine Market?

Recombinant vaccines are produced using genetic engineering techniques, which allows for more precise targeting of the virus or bacteria being targeted. This technology has been used to develop new vaccines, including the Shingrix vaccine for shingles. The growing use of recombinant vaccines offers several advantages over traditional vaccines, including improved safety, efficacy, and ease of production. As a result, they are becoming increasingly popular among healthcare providers and patients. This vaccine contains purified parts of pathogen that are antigenic, or necessary to elicit a protective immune response.

In addition to the benefits of recombinant vaccines, other factors such as the aging population, increasing healthcare expenditure, and rising awareness regarding the importance of preventive healthcare are expected to contribute to the growth of the zoster vaccine market. Aging comes with several health problems such as a weak immune system, which make the old population susceptible to infections like shingles. The increasing geriatric population globally estimated at 3 to 5 cases per 1000 individuals annually is contributing to the growth of the zoster vaccine market and is expected to continue its growth throughout the forecast period.

Country/Region-wise

How the Increasing Prevalence of Chickenpox in North America will Drive the Zoster Vaccine Market?

The rising prevalence of chickenpox in North America boost the zoster vaccine market. Chickenpox and shingles are caused by the same virus, known as the varicella-zoster virus. While chickenpox is a common childhood illness, the virus can remain dormant in the body and reactivate later in life as shingles. Additionally, recommendations for shingles vaccine may be part of the public health response to chickenpox outbreaks, especially for those who are more susceptible due to age or underlying medical issues. For Instance, on 7 September 2022, 21,060 cases of chickenpox were recorded by Mexican health authorities (11,057 males and 10,003 women). This is a significantly higher number than the 8,897 cases reported in 2021, a 137% rise. The likelihood of developing shingles is increased by the high prevalence of chickenpox.

The rising healthcare expenditure in North America has led to a surge in demand for the Zoster vaccine, thereby driving the growth of the market. This vaccine is highly effective in preventing shingles, which is a painful skin rash caused by the reactivation of the varicella-zoster virus.

Rising awareness regarding preventive healthcare will drive the zoster vaccine market. Public health campaigns and a growing focus on preventative measures are making people more aware of the importance of proactive healthcare. This shift in perspective is leading to a greater willingness to get vaccinated against diseases like shingles. People are becoming more informed about the potential complications of shingles, such as PHN, and understand the value of vaccination in preventing this debilitating condition. This growing awareness will likely lead to a significant increase in the demand for zoster vaccines in the coming years.

Will Growing Awareness of Government Vaccine Programs in Asia Pacific Drive the Zoster Vaccine Market?

Growing awareness of government vaccine programs in the Asia-Pacific region is expected to drive the demand for zoster vaccines and contribute to the growth of the market. Many governments in the region have launched vaccination programs to prevent various diseases, including shingles. These programs aim to increase awareness about vaccination and make vaccines more accessible to the population, especially older adults who are more susceptible to shingles.

For example, in Japan, the government has included the zoster vaccine in its national vaccination program for older adults, which covers the cost of the vaccine for eligible individuals. Additionally, in India, the government has launched various vaccination programs to prevent diseases such as hepatitis, influenza, and pneumococcal disease, which are also expected to increase awareness about the importance of vaccination and drive the demand for zoster vaccine.

Changing lifestyles in Asia-Pacific are expected to drive the zoster vaccine market. As people in the region become more health-conscious and adopt healthier lifestyles, the risk of developing shingles may decrease. However, the demand for zoster vaccine is still expected to increase as people become more aware of the importance of vaccination and take preventive measures to protect themselves against the disease.

Furthermore, government initiatives are expected to boost the growth of the market and encourage more manufacturers to invest in the development of new and more effective vaccines for shingles.

Competitive Landscape

The zoster vaccine market, while experiencing promising growth, is a concentrated landscape with a few key players vying for dominance. The zoster vaccine market is dynamic and competitive and will benefit public health. It can lead to the development of more effective, accessible, and affordable vaccines, offering broader protection against shingles and its debilitating complications. The interplay between established players, innovative newcomers, and regulatory bodies will define the future of the zoster vaccine market.

Some of the prominent players operating in the zoster vaccine market include:

  • GSK plc
  • Merck & Co., Inc.
  • Curevo Inc
  • Geneone Life Science
  • SK bioscience

Latest Developments

  • In February 2023, Pfizer Inc. and BioNTech SE launched a phase 1/2 trial to investigate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against varicella-zoster virus (VZV), which causes shingles, a severe condition referred to as herpes zoster, or HZ
  • In April 2023, GSK launched an anti-shingles vaccine in India. The vaccine is used to prevent herpes zoster and neuralgia in adults aged 50 years old
  • In February 2023, Jiangsu Recbio Technology Co., Ltd completed the first batch of subject enrollment for its adjuvant recombinant shingles vaccine, REC610.

Zoster Vaccine Market, By Category

  • Product Type
  • Zostavax
  • Shingrix
  • SKYZoster
  • Vaccine Type:
  • Recombinant Vaccine
  • Live Attenuated Vaccine
  • Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Age Group:
  • Above 50 to 65 Age
  • Above 65 Age
  • Above 18 to 50 Age
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 THOUGHT LEADERSHIP OPINION

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL ZOSTER VACCINE MARKET OVERVIEW
  • 3.2 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
  • 3.3 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) ESTIMATES AND FORECAST, 2024-2030
  • 3.4 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
  • 3.5 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.6 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
  • 3.7 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.8 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
  • 3.9 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
  • 3.10 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
  • 3.11 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
  • 3.12 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
  • 3.13 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
  • 3.14 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
  • 3.15 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
  • 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

  • 4.1 GLOBAL ZOSTER VACCINE MARKET EVOLUTION
  • 4.2 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
    • 4.3.1 INCREASING PREVALENCE OF HERPES ZOSTER
    • 4.3.2 GROWING AWARENESS ABOUT HERPES ZOSTER
  • 4.4 MARKET RESTRAINTS
    • 4.4.1 HIGH COST OF VACCINES
  • 4.5 MARKET TRENDS
    • 4.5.1 AGEING POPULATION
  • 4.6 MARKET OPPORTUNITY
    • 4.6.1 DEVELOPMENTS IN VACCINE TECHNOLOGY
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 THREAT OF SUBSTITUTES
    • 4.7.3 BARGAINING POWER OF SUPPLIERS
    • 4.7.4 BARGAINING POWER OF BUYERS
    • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 4.8 MACROECONOMIC ANALYSIS
  • 4.9 VALUE CHAIN ANALYSIS
  • 4.10 PRICING ANALYSIS
  • 4.11 REGULATIONS
    • 4.11.1 SAUDI FOOD AND DRUG AUTHORITY (SFDA)
  • 4.12 PRODUCT LIFELINE

5 MARKET, BY PRODUCT TYPE

  • 5.1 OVERVIEW
  • 5.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
  • 5.3 ZOSTAVAX
  • 5.4 SHINGRIX
  • 5.5 SKYZOSTER

6 MARKET, BY VACCINE TYPE

  • 6.1 OVERVIEW
  • 6.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
  • 6.1 LIVE ATTENUATED VACCINE
  • 6.2 RECOMBINANT VACCINE

7 MARKET, BY SALES CHANNEL

  • 7.1 OVERVIEW
  • 7.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
  • 7.3 PRIVATE
  • 7.4 PUBLIC

8 MARKET, BY AGE GROUP

  • 8.1 OVERVIEW
  • 8.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
  • 8.3 ABOVE 50 TO 65 AGE
  • 8.4 ABOVE 65 AGE
  • 8.5 ABOVE18 TO 50 AGE

9 MARKET, BY GEOGRAPHY

  • 9.1 OVERVIEW
    • 9.1.1 INDIA
    • 9.1.2 TAIWAN
    • 9.1.3 THAILAND
    • 9.1.4 SAUDI ARABIA
    • 9.1.5 UAE
    • 9.1.6 TURKEY
    • 9.1.7 BRAZIL
    • 9.1.8 MEXICO
    • 9.1.9 ARGENTINA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE SCENARIO
  • 10.3 COMPANY MARKET RANKING ANALYSIS
  • 10.4 COMPANY REGIONAL FOOTPRINT
  • 10.5 COMPANY INDUSTRY FOOTPRINT
  • 10.6 ACE MATRIX
    • 10.6.1 ACTIVE
    • 10.6.2 CUTTING EDGE
    • 10.6.3 EMERGING
    • 10.6.4 INNOVATORS

11 COMPANY PROFILES

  • 11.1 GLAXOSMITHKLINE PLC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 COMPANY INSIGHTS
    • 11.1.3 SEGMENT BREAKDOWN
    • 11.1.4 PRODUCT BENCHMARKING
    • 11.1.5 KEY DEVELOPMENTS
    • 11.1.6 SWOT ANALYSIS
    • 11.1.7 WINNING IMPERATIVES
    • 11.1.8 CURRENT FOCUS & STRATEGIES
    • 11.1.9 THREAT FROM COMPETITION
  • 11.2 MERCK & CO., INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 COMPANY INSIGHTS
    • 11.2.3 SEGMENT BREAKDOWN
    • 11.2.4 PRODUCT BENCHMARKING
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 WINNING IMPERATIVES
    • 11.2.7 CURRENT FOCUS & STRATEGIES
    • 11.2.8 THREAT FROM COMPETITION
  • 11.3 SK BIOSCIENCES (SK CHEMICALS)
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 COMPANY INSIGHTS
    • 11.3.3 PRODUCT BENCHMARKING
    • 11.3.4 SWOT ANALYSIS
    • 11.3.5 WINNING IMPERATIVES
    • 11.3.6 CURRENT FOCUS & STRATEGIES
    • 11.3.7 THREAT FROM COMPETITION
  • 11.4 GENEONE LIFE SCIENCE
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 COMPANY INSIGHTS
    • 11.4.3 PRODUCT BENCHMARKING
  • 11.5 PFIZER
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 COMPANY INSIGHTS
    • 11.5.3 SEGMENT BREAKDOWN
    • 11.5.4 PRODUCT BENCHMARKING
    • 11.5.5 KEY DEVELOPMENTS
  • 11.6 CANSINO BIOLOGICS INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 COMPANY INSIGHTS
    • 11.6.3 SEGMENT BREAKDOWN
    • 11.6.4 PRODUCT BENCHMARKING
  • 11.7 VACCITECH
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 COMPANY INSIGHTS
    • 11.7.3 PRODUCT BENCHMARKING
    • 11.7.4 KEY DEVELOPMENTS
  • 11.8 INOVIO PHARMACEUTICALS, INC.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 COMPANY INSIGHTS
    • 11.8.3 SEGMENT BREAKDOWN
  • 11.9 CUREVO INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 COMPANY INSIGHTS
    • 11.9.3 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 3 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 4 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 5 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 6 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 7 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 8 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • TABLE 9 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
  • TABLE10 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE11 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE12 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE13 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE14 INDIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE15 INDIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE16 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE17 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE18 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE19 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 20 TAIWAN ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 21 TAIWAN ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 22 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 23 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 24 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 25 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 26 THAILAND ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 27 THAILAND ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 28 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 29 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 30 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 31 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 32 SAUDI ARABIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 33 SAUDI ARABIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 34 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 35 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 36 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 37 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 38 UAE ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 39 UAE ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 40 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 41 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 42 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 43 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 44 TURKEY ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 45 TURKEY ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 46 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 47 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 48 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 49 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 50 BRAZIL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 51 BRAZIL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 52 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 53 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 54 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 55 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 56 MEXICO ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 57 MEXICO ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 58 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 59 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 60 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 61 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 62 ARGENTINA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 63 ARGENTINA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 64 COMPANY REGIONAL FOOTPRINT
  • TABLE 65 COMPANY INDUSTRY FOOTPRINT
  • TABLE 66 GLAXOSMITHKLINE PLC.: PRODUCT BENCHMARKING
  • TABLE 67 GLAXOSMITHKLINE PLC.: KEY DEVELOPMENTS
  • TABLE 68 GLAXOSMITHKLINE PLC.: WINNING IMPERATIVES
  • TABLE 69 MERCK & CO., INC.: PRODUCT BENCHMARKING
  • TABLE 70 MERCK & CO., INC.: WINNING IMPERATIVES
  • TABLE 71 SK BIOSCIENCES (SK CHEMICALS): PRODUCT BENCHMARKING
  • TABLE 72 SK BIOSCIENCES (SK CHEMICALS): WINNING IMPERATIVES
  • TABLE 73 GENEONE LIFE SCIENCE: PRODUCT BENCHMARKING
  • TABLE 74 PFIZER: PRODUCT BENCHMARKING
  • TABLE 75 PFIZER: KEY DEVELOPMENTS
  • TABLE 76 CANSINO BIOLOGICS INC.: PRODUCT BENCHMARKING
  • TABLE 77 VACCITECH: PRODUCT BENCHMARKING
  • TABLE 78 VACCITECH: KEY DEVELOPMENTS
  • TABLE 79 CUREVO INC.: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE1 GLOBAL ZOSTER VACCINE MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 THOUGHT LEADERSHIP OPINION
  • FIGURE 6 SUMMARY
  • FIGURE 7 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
  • FIGURE 8 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) AND FORECAST, 2024-2030
  • FIGURE 9 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
  • FIGURE10 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • FIGURE11 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
  • FIGURE12 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • FIGURE13 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
  • FIGURE14 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
  • FIGURE15 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
  • FIGURE16 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
  • FIGURE17 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
  • FIGURE18 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
  • FIGURE19 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
  • FIGURE 20 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
  • FIGURE 21 FUTURE MARKET OPPORTUNITIES
  • FIGURE 22 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
  • FIGURE 23 MARKET DRIVERS IMPACT ANALYSIS
  • FIGURE 24 RESTRAINTS IMPACT ANALYSIS
  • FIGURE 25 KEY TRENDS
  • FIGURE 26 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 ZOSTER VACCINES MARKET PRICES BY REGION UNIT/DOSE)
  • FIGURE 28 PRODUCT LIFELINE: ELECTRICAL STEEL SHEET MARKET
  • FIGURE 29 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE
  • FIGURE 30 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
  • FIGURE 31 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE
  • FIGURE 32 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
  • FIGURE 33 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL
  • FIGURE 34 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
  • FIGURE 35 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP
  • FIGURE 36 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
  • FIGURE 37 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • FIGURE 38 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
  • FIGURE 39 INDIA MARKET SNAPSHOT
  • FIGURE 40 TAIWAN MARKET SNAPSHOT
  • FIGURE 41 THAILAND MARKET SNAPSHOT
  • FIGURE 42 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 43 UAE MARKET SNAPSHOT
  • FIGURE 44 HERPES ZOSTER INCIDENCE PER ONE MILLION POPULATION, BY AGE, 2018 & 2019
  • FIGURE 45 TURKEY MARKET SNAPSHOT
  • FIGURE 46 NUMBER OF HERPS ZOSTER DIAGNOSES REPORTED IN MARCH -AUGUST (2018-2020)
  • FIGURE 47 BRAZIL MARKET SNAPSHOT
  • FIGURE 48 MEXICO MARKET SNAPSHOT
  • FIGURE 49 ARGENTINA MARKET SNAPSHOT
  • FIGURE 50 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 51 COMPANY MARKET RANKING ANALYSIS
  • FIGURE 52 ACE MATRIC
  • FIGURE 53 GLAXOSMITHKLINE PLC.: COMPANY INSIGHT
  • FIGURE 54 GLAXOSMITHKLINE PLC.: BREAKDOWN
  • FIGURE 55 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
  • FIGURE 56 MERCK & CO., INC.: COMPANY INSIGHT
  • FIGURE 57 MERCK & CO., INC.: BREAKDOWN
  • FIGURE 58 MERCK & CO., INC.: SWOT ANALYSIS
  • FIGURE 59 SK BIOSCIENCES (SK CHEMICALS): COMPANY INSIGHT
  • FIGURE 60 SK BIOSCIENCES (SK CHEMICALS): SWOT ANALYSIS
  • FIGURE 61 GENEONEE LIFE SCIENCE: COMPANY INSIGHT
  • FIGURE 62 PFIZER: COMPANY INSIGHT
  • FIGURE 63 PFIZER: BREAKDOWN
  • FIGURE 64 CANSINO BIOLOGICS INC.: COMPANY INSIGHT
  • FIGURE 65 CANSINO BIOLOGICS INC.: BREAKDOWN
  • FIGURE 66 VACCITECH: COMPANY INSIGHT
  • FIGURE 67 INOVIO PHARMACEUTICALS, INC.: COMPANY INSIGHT
  • FIGURE 68 INOVIO PHARMACEUTICALS, INC.: BREAKDOWN
  • FIGURE 69 CUREVO INC.: COMPANY INSIGHT